David Bailey Buys 4,852 Shares of KindlyMD (NASDAQ:NAKA) Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey bought 4,852 shares of the business’s stock in a transaction dated Thursday, August 20th. The shares were bought at an average cost of $6.27 per share, for a total transaction of $30,422.04. Following the purchase, the chief executive officer directly owned 3,185,246 shares in the company, valued at approximately $19,971,492.42. This represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

KindlyMD Price Performance

NAKA stock traded up $0.76 during trading on Friday, reaching $7.06. The company had a trading volume of 451,586 shares, compared to its average volume of 199,173. KindlyMD, Inc. has a 52 week low of $3.33 and a 52 week high of $422.40. The company has a market cap of $126.37 million, a P/E ratio of -0.20 and a beta of 15.95. The business has a 50 day moving average of $4.48 and a 200 day moving average of $7.24.

KindlyMD (NASDAQ:NAKA) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) EPS for the quarter. The company had revenue of $35.87 million during the quarter. KindlyMD had a negative return on equity of 63.45% and a negative net margin of 1,067.93%. Research analysts expect that KindlyMD, Inc. will post -11.31 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NAKA. Alyeska Investment Group L.P. bought a new stake in KindlyMD in the fourth quarter worth $8,993,000. ParaFi Capital LP bought a new position in shares of KindlyMD during the third quarter valued at $443,055,000. Hunting Hill Global Capital LLC purchased a new position in shares of KindlyMD in the 4th quarter worth about $4,672,000. Yorkville Advisors Global LP purchased a new position in shares of KindlyMD in the 4th quarter worth about $3,265,000. Finally, UBS Group AG bought a new position in KindlyMD in the 4th quarter worth about $2,958,000.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. TD Cowen increased their price objective on KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, July 27th. Wall Street Zen raised shares of KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, KindlyMD presently has a consensus rating of “Hold” and a consensus price target of $22.33.

Trending Headlines about KindlyMD

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.